Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J, Sluijter M, Schaap G, Göynük B, Lloyd K, Ovcinnikovs V, Zom GG, Marijnissen RJ, Groeneveldt C, Griffioen L, Sandker GGW, Heskamp S, van der Burg SH, Arakelian T, Ossendorp F, Arens R, Schuurman J, Kemper K, van Hall T. Middelburg J, et al. Nat Commun. 2024 Jan 2;15(1):48. doi: 10.1038/s41467-023-44308-6. Nat Commun. 2024. PMID: 38167722 Free PMC article.
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.
Middelburg J, Ghaffari S, Schoufour TAW, Sluijter M, Schaap G, Göynük B, Sala BM, Al-Tamimi L, Scheeren F, Franken KLMC, Akkermans JJLL, Cabukusta B, Joosten SA, Derksen I, Neefjes J, van der Burg SH, Achour A, Wijdeven RHM, Weidanz J, van Hall T. Middelburg J, et al. Cell Rep. 2023 Dec 26;42(12):113516. doi: 10.1016/j.celrep.2023.113516. Epub 2023 Dec 3. Cell Rep. 2023. PMID: 38048225 Free article.
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: middelburg j. J Immunother Cancer. 2020 Oct;8(2):e001191. doi: 10.1136/jitc-2020-001191. J Immunother Cancer. 2020. PMID: 33082167 Free PMC article.